MorphoSys AG (MOR)

Market Cap	2.93B
Revenue (ttm)	264.75M
Net Income (ttm)	-210.82M
Shares Out	150.65M
EPS (ttm)	-1.50
PE Ratio	n/a
Forward PE	322.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	897,627
Open	18.83
Previous Close	18.50
Day's Range	18.80 - 19.50
52-Week Range	4.19 - 19.50
Beta	0.60
Analysts	Hold
Price Target	12.13 (-37.28%)
Earnings Date	Apr 29, 2024

About MOR

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 9, 1999
• Employees: 524
• Stock Exchange: NASDAQ
• Ticker Symbol: MOR

Financial Performance

In 2023, MorphoSys AG's revenue was 238.28 million, a decrease of -14.37% compared to the previous year's 278.27 million. Losses were -189.73 million, 25.6% more than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 5 analysts, the average rating for MOR stock is "Hold." The 12-month stock price forecast is $12.13, which is a decrease of -37.28% from the latest price.

Price Target

$12.13

(-37.28% downside)

Analyst Consensus: Hold